NXP900: NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
Osimertinib: Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor
Study summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Provide written informed consent.
2. 18 years old or older.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
Exclusion Criteria:
1. Subject's cancer has a known oncogenic driver alteration other than EGFR.
2. Known EGFR mutations that cause resistance to osimertinib
3. Known human epidermal growth factor receptor 2 (HER2) overexpression
4. Any contraindications to treatment with osimertinib
Primary outcome measure(s)
Number of patients with treatment related adverse events and/or clinical laboratory abnormalities — Up to 30 days post treatment
Objective response rate (ORR) — Up to approximately 12 months Best response of complete response (CR) or partial response (PR) per RECIST 1.1
Duration of Response (DoR) — Up to approximately 12 months Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
Disease Control Rate (DCR) — Up to approximately 12 months The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
Trial sites (6)
Facility
City
Region
Status
Maryland Oncology Hematology
Calverton
Maryland
Recruiting
Massachusetts General Hospital
Boston
Massachusetts
Not Yet Recruiting
Willamette Valley Cancer Institute and Research Center
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.